Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Edesa Biotech, Inc.
Report date October 12, 2018 · Filed October 13, 2018
Section 16 reporting ended · disclosed 2018-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 20,741 |
Reported balance
After 2018-10-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-10-12 · Sale · Disposed 7,047 · Balance 20,741 F1: The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2018 Filed Oct 13, 2018 01:50 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon Shares, without par value | 7,047 | $1.31 | $9,259.76 |
DisclosureSEC source: 0001144204-18-053713 · tv504785_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,741 F1 · balance_after: The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 10:11 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon Shares, without par value | 4,366 | $0.81 | $3,514.63 |
DisclosureSEC source: 0001144204-18-018810 · tv490213_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 0 Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:23 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · derivative · entry 7 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:23 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon shares, without par value | 3,500 | $0.80 | $2,789.50 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 5 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 4,366 Read SEC document |
| March 09, 2018 Filed Mar 15, 2018 00:23 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon shares, without par value | 7,000 | $0.81 | $5,635.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 4 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 7,866 Read SEC document |
| February 28, 2018 Filed Mar 15, 2018 00:23 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon shares, without par value | 7,000 | $0.79 | $5,530.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 3 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 14,866 Read SEC document |
| February 26, 2018 Filed Mar 15, 2018 00:23 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon shares, without par value | 7,000 | $0.79 | $5,530.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 2 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 21,866 Read SEC document |
| February 22, 2018 Filed Mar 15, 2018 00:23 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | SaleCommon Shares, without par value | 7,800 | $0.78 | $6,115.20 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 28,866 Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 20:45 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantCommon Shares, without par value | 134,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-034654 · v469931_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,189 F1 · shares: Shares issued under the issuer's Performance Share Plan. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:01 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016844 · v462723_4.xml · derivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 22:03 UTC | Edesa Biotech, Inc. SBOT · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001144204-16-140715 · v455479_4.xml · derivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2023-12-20 F1 · derivative.exercise_date: Option grant under the 2013 Fixed Share Option Plan, which shall vest as to one-third immediately, as to one-third on December 20, 2017 and as to the remaining one-third on June 20, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.